Digital transformation in supply chain management
Karsten Smet, CEO of ACI Group, looks at ways the pharmaceutical and agrochemical industries can adapt to changing times
Karsten Smet, CEO of ACI Group, looks at ways the pharmaceutical and agrochemical industries can adapt to changing times
Italian CDMO and API producer Olon Group has acquired its compatriot HuvePharma Italia, which makes APIs and advanced intermediates via chemical synthesis, from the Huvepharma EOOD group. This is part of Olon’s strategy of growth, consolidation and expansion, both internally and through acquisitions
Barentz International has acquired distributors in two different regions in short order. The acquisition of Insuqui in Paraguay followed a few weeks after that of the Anshul Life Sciences Group in India. Terms were not disclosed in either deal and the existing management teams will remain in place.
Agilent Technologies, a major player in analytical and clinical laboratory services, has agreed to acquire Canadian biotech and pharmaceutical CDMO Biovectra from HIG Capital in a $925 million deal that is expected to close before 2025. This covers all Biovectra’s employees and sites in Prince Edward Island and Nova Scotia.
“The acquisition expand Agilent’s end-to-end biopharma solutions with Biovectra’s biologics capabilities to accelerate drug development and manufacturing,” the two companies stated. Industry rumour had previously linked Biovectra with Thermo Fisher.
Following public consultation, CEFIC has presented a paper with six recommendations in support of the European Commission’s proposals to update the existing EU regulation on pharmaceutical precursors. These are:
CordenPharma is to spend about €900 million over the next three years to expand its peptide technology platform, with investments on both sides of the Atlantic. This will be the largest strategic investment to date for the company, which is owned by pan-European private equity firm Astorg and aims to achieve €1 billion/year in sales from peptides
Navin Molecular, an Indian-based CDMO that is part of Navin Fluorine, has announced plans to build $35 million, 9,000 m2 multi-purpose GMP plant at Dewas. This is due to be completed in Q2 225. The facility will add 200 m3 of capacity, taking the total at Dewas to 420. It will support existing commercial-scale projects, as well as meeting future demands, the company said.